The U.S. Food and Drug Administration (FDA) has issued a warning to consumers about counterfeit versions of Novo Nordisk's diabetes drug, Ozempic, which have been discovered in the country's drug supply chain. The health regulator is currently investigating these counterfeit Ozempic injections and has seized thousands of units. However, they believe that some of these counterfeit drugs may still be available for purchase.
Novo Nordisk, a Danish pharmaceutical company, is working with the FDA to test the seized products. Unfortunately, at this stage, there is no information available regarding the identity, quality, or safety of these drugs. The seizures occurred in warehouses outside of Novo Nordisk's authorized supply chain.
According to the FDA, the needles from the counterfeit injections are also fake, raising concerns about their sterility. This poses an additional risk of infection for patients who may use these counterfeit drugs. The agency has also discovered other counterfeit components, including the pen label, accompanying information about healthcare professionals and patients, as well as the carton.
To address this issue, the FDA has advised drug distributors, retail pharmacies, healthcare practitioners, and patients to carefully inspect the drugs they have received. Specifically, they should avoid distributing, using, or selling units labeled with lot number NAR0074 and serial number 430834149057.
While there have been reports of five adverse events associated with the use of drugs from this lot, the FDA has stated that these incidents were consistent with the known side effects of authentic Ozempic.
The demand for Novo Nordisk's drugs, including Ozempic and Wegovy, which is approved for obesity, is currently exceeding the company's supply in the United States, Germany, and Britain. As a result, Novo Nordisk has taken measures to restrict the supply of certain doses of Wegovy to the U.S. market.
While Wegovy is not approved for the treatment of diabetes, individuals in the United States and Europe have been using Ozempic, its diabetes counterpart, "off-label" to achieve significant weight loss. This off-label use has further increased the demand for these medications.
At present, the FDA is actively working with Novo Nordisk to investigate these counterfeit drugs further. In the meantime, it is crucial for medical professionals, patients, and distributors to remain vigilant and report any suspicious incidents or drugs related to Ozempic to the FDA for immediate action.